home / stock / auph / auph news

AUPH News and Press, Aurinia Pharmaceuticals Inc From 07/23/20

Stock Information
Company Name: Aurinia Pharmaceuticals Inc
Stock Symbol: AUPH
Market: NASDAQ
Website: auriniapharma.com
Menu
AUPH AUPH Quote AUPH Short AUPH News AUPH Articles AUPH Message Board
Get AUPH Alerts

News, Short Squeeze, Breakout and More Instantly...
AUPH - TNXP, CBAY, AUPH and BNTX among midday movers

Gainers:  Milestone Pharmaceuticals (NASDAQ: MIST ) +105% . More news on: Milestone Pharmaceuticals Inc., RigNet, Inc., Brightcove Inc., Stocks on the move, , Read more ...

AUPH - AUPH, NAK among premarket losers

Mexco Energy (NYSEMKT: MXC ) -9% . More news on: Mexco Energy Corporation, Northern Dynasty Minerals Ltd., Limelight Networks, Inc., Stocks on the move, , Read more ...

AUPH - Aurinia prices equity offering at $15

Aurinia Pharmaceuticals (NASDAQ: AUPH ) has priced its public offering of ~13.3M common shares at $15.00/share, for gross proceeds of ~$200M. More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, , Read more ...

AUPH - Aurinia Prices US$200 Million Public Offering of Common Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 13,333,33...
AUPH - Why Aurinia Pharmaceuticals Is Up Today

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) are up by 10.4% as of 11:15 a.m. EDT on Wednesday, after the company announced that the U.S. Food and Drug Administration (FDA) accepted the filing of a New Drug Application (NDA) for Voclosporin.  Voclosporin is a potential treatment fo...

AUPH - NAK, EXK among premarket gainers

Mexco Energy (NYSEMKT: MXC ) +153% . More news on: Mexco Energy Corporation, Oblong Inc., Oragenics, Inc., Stocks on the move, , Read more ...

AUPH - Aurinia Pharma's voclosporin nabs accelerated review for kidney inflammation

The FDA has accepted Aurinia Pharmaceuticals' (NASDAQ: AUPH ) New Drug Application (NDA) for voclosporin, as a potential treatment for lupus nephritis, an inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus. More news on: Aurinia Pharmaceuticals In...
AUPH - Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis

- FDA grants Priority Review and sets PDUFA date of January 22, 2021 - Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indicat...

AUPH - Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

- Voclosporin ophthalmic solution (VOS) results anticipated in the fourth quarter of 2020 – Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclos...

AUPH - Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020

Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that additional safety data from the completed AURORA pivotal ...
Previous 10 Next 10